Talent one indian pharma updates june 2015

Website: http://www.talentone.in
Headquarters:TalentOne.In,4thFloor,YSR Mansion,SarjapurRoad,NearHDFCBank, Bangalore-560035,Karnataka,India
http://www.ibef.org/industry/pharmaceutica
l-india/showcase
Introduction
The Indian pharmaceuticals market isthird largest in terms of volume andthirteen largest in terms ofvalue,as pera pharmaceuticals sectoranalysisreport
by equity master. Themarket isdominated majorlyby branded genericswhich constitutenearly70 to 80 per cent of the market. Considered to be a highly
fragmented industry,consolidation has increasinglybecome animportant featureof theIndian pharmaceutical market.
India has achieved an eminent globalposition in pharma sector. The countryalso hasa hugepool ofscientists and engineerswho have thepotential to take

the industry to a very high level.
The UN-backed Medicines Patents Pool hassigned six sub-licenceswith Aurobindo,Cipla,Desano,Emcure,Hetero Labs and Laurus Labs,allowing themto
make generic anti-AIDS medicineTenofovir Alafenamide (TAF)for112developing countries.
Market Size
The Indian pharmaceutical industryis estimated to grow at 20 per cent compound annual growth rate(CAGR)over the next five years,asper India Ratings,a
Fitch Group company. Indian pharmaceutical manufacturing facilities registered with USFood and Drug Administration(FDA)ason March 2014 wasthe
highest at 523for any countryoutsidethe US.
We expect the domestic pharma market to grow at 10-12per cent in FY15ascompared to 9 percent in FY14,as per a recent report fromCentrumBroking.
The domestic pharma growth rate was 11.9 per cent in October 2014,highlighted the report.
Gujarat clocked thehighest growth rate in pharmaceuticalsmarket at 22.4 per cent during November 2014,surpassingthe industrygrowth rate,which grew
by 10.9 per cent,as per datafromthe market research firmAIOCD Pharmasofttech AWACS.
Also,growing at an averagerate of about 20 percent,India's biotechnology industry comprising bio-pharmaceuticals,bio-services,bio-agriculture,bio-
industry and bioinformatics may reach the US$ 7billion mark bythe end ofFY15,according to anindustry body. Biopharmais the largest sector contributing
about 62per cent of the total revenue,with revenue generationto the tune ofover Rs12,600 crore(US$ 2.03billion). The bio-pharma sector comprises
vaccines,therapeuticsand diagnostics.
Investments
The Union Cabinet has given its approval to amend the existing FDI policyin the pharmaceuticalsector in order to cover medicaldevices. TheCabinet has
allowed FDI up to 100 per cent underthe automatic route for manufacturingof medicaldevicessubject to specified conditions.
The drugs and pharmaceuticalssector attracted cumulative foreign direct investment (FDI)inflows worth US$ 12,813.02million between April 2000and
December 2014,according to data released by theDepartment of Industrial Policy and Promotion (DIPP).
Some of the major investmentsin the Indian pharmaceuticalsector are as follows:
Stelis Biopharma has announced the ground-breaking for construction ofits customised,multi-product,biopharmaceuticalmanufacturing facilityat Bio-
Xcell Biotechnology Parkin Nusajaya,Johor,Malaysia'sparkand ecosystemforindustrial and healthcare biotechnology at a totalproject investment
amount of US$ 60 million.
Pharma major StridesArcolab hasentered into a licensing agreement with US-based Gilead SciencesInc to manufactureand distribute the latter's low-cost
Tenofovir Alafenamide(TAF)product used forHIV treatment in developing countries. The licence to manufactureGilead's low-cost drug extends to 112
countries.
Apollo HospitalsEnterprise(AHEL)plans to add another2,000 beds overthe next two financial years,at acost ofaround Rs 1,500 crore (US$242.57million),
as per Mr Prathap CReddy,Founderand Executive Chairman,Apollo Hospitals.
CDC,the UK’s development finance institution,has invested US$ 48 million in Narayana Hrudayalaya hospitals,a multi-specialityhealthcare provider. With
this investment,NarayanaHealth will expand affordabletreatment ineastern,central and western India.
Cadila HealthcareLtd hasannounced thelaunch of abiosimilar forAdalimumab - theworld’s largest selling drugfor rheumatoid arthritisand other auto
immune disorders. The drug willbe marketed under the brand nameExemptia at one-fifth of theprice forthe branded version-Humira. Cadila’s biosimilar is
the first to be launched by any company in the worldand isa fingerprint match with the original in terms ofsafety,purityand potency ofthe product,asper
the company.
Torrent Pharmaceuticalshas entered into an exclusive licensing agreement with RelianceLife Sciencesfor marketing three biosimilars inIndia — Rituximab,
Adalimumab and Cetuximab.
Piramal Enterprises Ltd has acquired US-based ColdstreamLaboratories for US$ 30.6 million in an all-cash transaction.
Indian ImmunologicalsLtd (IIL)plansto set up anew vaccinemanufacturing facility in Pondicherry with an investment of Rs 300crore(US$ 48.53million).
SRF Ltd has acquired Global DuPont Dymel,the pharmaceutical propellant businessof DuPont,forUS$ 20 million.
Government Initiatives
The Addendum2015of the Indian Pharmacopoeia(IP)2014 is published bythe Indian PharmacopoeiaCommission (IPC)on behalf ofthe Ministryof Health &
Family Welfare,Government ofIndia. Theaddendumwould play asignificant rolein improving the qualityof medicineswhich in turnpromote public health
and accelerate the growth and development of pharma sector.
The Government of India has unveiled 'Pharma Vision 2020' aimed at making India a globalleaderin end-to-end drug manufacture. It has reduced approval
time for new facilities to boost investments. Further,the government hasalso put in placemechanisms such asthe Drug PriceControl Order and the National
Pharmaceutical Pricing Authority to address theissue ofaffordability and availability ofmedicines.
Romania is keen to tie up with the Indian pharmaceutical companies for research and develop new drugs. "Romania willcollaborate with India for license
acquisition to sale India's drugs in Europe," said Mr Mario Crute,Counselor in Ministry ofhealth in Romaniaat GCCI. The country will tieup with the Indian
pharmaceuticalcompaniesforresearch and develop new drugs.
Some of the major initiatives taken by the government to promote the pharmaceutical sector in India areas follows:
Indian and global companieshaveexpressed 175investment intentions worth Rs1,000 crore(US$ 161.78 million)in the pharmaceutical sector ofGujarat.
The memorandums of understanding (MoUs)would be signed during the Vibrant Gujarat Summit.
Telangana has proposed to set up India's largest integrated pharmaceutical city spread over11,000 acresnear Hyderabad,complete with effluent treatment
plants and a township for employees,in a bid to attract investment of Rs 30,000crore(US$ 4.85billion)in phases. Hyderabad,which isknown as the bulk
drug capital of India,accounts fornearlya fifth ofIndia'sexports ofdrugs,which stood at Rs 90,000crore(US$ 14.56 billion)in 2013-14.
Road Ahead
The Indian pharma market size isexpected to grow to US$85billionby 2020. The growth in Indian domestic market will beon backof increasing consumer
spending,rapid urbanisation,raising healthcareinsurance and so on.
Going forward,better growth in domesticsaleswill depend on the abilityof companies to align their product portfolio towardschronic therapiesfor diseases
such as such as cardiovascular,anti-diabetes,anti-depressants and anti-cancers areon the rise.
Moreover,the government hasbeentaking several cost effective measures in order to bring down healthcareexpenses. Thus,governments are focusing on

speedy introduction of generic drugs into themarket. Thistoo will benefit Indian pharma companies. In addition,the thrust on rural health programmes,life
saving drugs and preventive vaccines also augurs well for the pharma companies.
Exchange rate used INR 1= US$ 0.016 as on February26,2015
References: Consolidated FDI Policy,Department of Industrial Policy &Promotion (DIPP),PressInformation Bureau (PIB),MediaReports,Pharmaceuticals
Export Promotion Council
Last Updated:March, 2015
Indiaisexpectedtobe the third-largestglobalgenericactive pharmaceutical ingredient(API) merchantmarketby2016,
witha 7.2 percent marketshare.The
countryaccounts for the secondlargestnumberof AbbreviatedNew DrugApplications(ANDAs) andisthe world’s
leaderinDrug Master Files(DMFs) applicationswiththe US.
The country's pharmaceutical industryexpandedata compoundannual growthrate (CAGR) of 9.4 percent in2013 to
reach US$ 12 billionandisexpectedtoexpandat a CAGR of 23.9 per centto US$ 55 billionby2020. With72 per centof
marketshare,genericdrugsformthe largestsegmentof the Indianpharmaceutical sector.
In termsof value,exportsof pharmaceutical productsfromIndiaincreasedata CAGRof 26.1 per centto US$ 10.1 billion
duringFY06–13. Genericdrugsaccount for20 percentof global exportsintermsof volume,makingthe countrythe
largestproviderof genericmedicinesgloballyandexpectedtoexpandevenfurtherincomingyears.
The Governmentof Indiaplanstoset upa US$ 640 millionventurecapital fundtoboostdrugdiscoveryandstrengthen
pharma infrastructure.PharmaVision2020 by the government’sDepartmentof Pharmaceuticalsaimstomake Indiaa
majorhub for end-to-enddrugdiscovery.
With70 percentof India’spopulationresidinginrural areas,pharmacompanieshave immense opportunitiestotapthis
market.Variouscompaniesare investinginthe distributionnetworkinrural areas.Indiaalsohasthe potential toattract
huge investmentstoitsclinical trial market.
Sun Pharma scouting for more deals; may
spend $7bn
India's Sun PharmaceuticalsIndustriesLtd,emboldenedby its takeover ofdomestic rival Ranbaxy Laboratories,is willing to spend as much as $7billion on
further acquisitions,bankers familiar with the generic drugmaker's strategy said.
The just completed Ranbaxydeal,its biggest to date at $3.2billion,hasgivenIndia'sbiggest drugmaker sufficient scale in genericsand emerging markets to
think about its next step - beefing up expertise in higher margin products and gaining a bigg ..

Read more at:
http://economictimes.indiatimes.com/articleshow/47083282.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
CCI imposes penalty on pharma majors
GlaxosmithKline and Sanofi India
Read more at:
http://economictimes.indiatimes.com/articleshow/47557311.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
Competition Commission has imposed a penalty of Rs64 crore on drugmakersGlaxoSmithKline Pharmaceuticalsand Sanofifor collusive bidding in supply of
a meningitis vaccine to the government for Haj pilgrims.
The matter relatesto supply ofpolysaccharideQuadrivalent Meningococcal Meningitis (QMMV) vaccines and the complaint was filed by Bio-Med Pvt Ltd,
which also makes this drug. The complaint was also filed against the Health and Family Welfare Ministry.
ADVERTISING
Every year,the government invites tenders for purchase of meningitis vaccine that is required to be administered upon Haj pilgrims.
Apart fromimposing penalties,the Commission has directed GlaxoSmithKline and Sanofi to "cease and desist" fromanti-competitive practices.
A fine of Rs 60.45crore has been slapped on GlaxoSmithKline and Rs 3.04 crore on Sanofi,the Competition Commission of India (CCI)said.
Cipla gets USFDA approval for child-friendly
HIV drug delivery system
Indian pharma industry is one of the
biggest considering a population of
over 1.2 billion to be served.
Companies have been consistently

investing crores of rupees every year to
serve the best medication to the
people. Here is a list of the top 10
pharmaceutical companies in India in
2014, which are ranked on the basis of
their sales revenue
Top 10 Indian Pharma companies by sales revenue-
10. Wockhardt
WockhardtLtd. is an Indianpharma
company.Its headquartersarelocatedin
Mumbai,India.It was foundedby Habil
Khorakiwalainthe early1960sfrom the
acquisitionofWorliChemical Worksin
1959,incorporatedasWockhardtPvt. Ltd.,
in 1973andthen as WockhardtLtd. in1999.
Wockhardthas presencegloballywithits
presenceinRussia,Uganda,Brazil, Kenya,
Mexico,Vietnam,Ghana,Mauritius,
Philippines,Nigeria,Nepal,Tanzania,
Myanmar,Sri Lanka,LebanonandKuwait.
UK, followedby US is the biggestmarket
for Wokhardt. Wokhardtproduces
formulations,biopharmaceuticals,nutrition
products,vaccinesandactive
pharmaceuticalingredients(APIs). It has
employeestrengthof 7900on a global
scale.WockhardtHospitalsis a subsidiary
of the WockhardtGroup.Wockhardt’s
blockbusterdrugisToprolwhichisusedto
treat hypertension. Someof the key drugs
are Flonase,nasalsprayto treat
9. GlaxoSmithKline
GSK is a British pharmaandconsumer
healthcarecompany.Its headquarters
are locatedinBrentford, London.The
companywasfoundedby the mergerof
GlaxoWellcomeand SmithKline
Beecham plc in2000.It has employee
strength of over 99,000worldwide.The
companyproducesdrugsandvaccines
for diseaseslike asthma,diabetes,
cancer,infections,digestiveandmental
healthconditions.Theblockbuster
drugsof GSK areAdvair, Avodart,
Flovent, Augmentin,Lovaza, and
Lamictal.Theconsumerhealthcare
divisionof GSK includesnutritional
productsanddrinkslike Boost and
Horlicks,over-the-counter(OTC)
medicinesandoralhealthcareproducts
likeSensodyne. GSK has announced
that it willonlypay fees to doctorsfor
criticalfunctionsthathelpobtain
insightsinto specific diseaseslike
companysponsoredscientificadvisory
8. TorrentPharmaceuticals Ltd
TorrentPharmaceuticalsLtd.is an Indian
pharmacompany.Its headquartersarebased
in Ahmedabad.It was foundedby U.N. Mehta
with the nameof TrinityLaboratoriesLtd.It
has employeestrengthof 4000 acrossthe
world.TorrentPharmaceuticalsoperatesin
morethan 50countrieswithover 1000
products.It has 7 fullyownedsubsidiariesin
Germany, US, Russia,Phillippines,Brazil
andCanada.Thecompanyoperatesinthe
followingkeyareas: APIs, Formulations,
Discovery, MarketingandSalesof Drugs.
TheCompanywasthe first to launch
ranitidine(Ranitin),atenolol(Betacard),
nifedipine(Calcigard),domperidone
(Domstal),amiodorane(Cordarone),diltiazem
(Dilzem),Lisinopril(Listril),etc. in the Indian
market.TheCompanyisa leaderin the
Cardiovascularsegment.It is the thirdin the
industryin Gastro-IntestinalDrugssegment.
TorrentPharmalaunched,theworld’sfirst
‘polypill’CVpill, inCardiac care.Thecompany
launchedIndia’sfirstRimonabantcalled

congestion,Stalevo, usedto treat
Parkinson'sdisease,Comtan,Another drug
to treat Parkinson's.
 SalesRevenue: Rs. 2471.18cr.
services, clinicaltrialsandmarket
research.
 SalesRevenue: Rs. 2546.15
cr.
Rimoslim.It was alsothe first to launch
India’sfirst bulklaxative in tablet form
(Fibotab).
7. Ipca laboratories
IpcaLaboratoriesisan Indianpharma
Mumbai,India.It was foundedby K.B.
MehlaandDr. N.S. Tibrawalaalongwitha
groupof othersincludingmediacl
professionalsandbusinessmenin1949.
Later, in 1975,the companywastaken over
by Amitabh Bachchan,Jaya Bachchan,
Ajitabh Bachchan,P.C.GodhaandM.R.
Chandurkar.IpcaLabshas an employee
baseof 8000across36countries.It is one
of the largest suppliersof APIs. It
manufacturesmorethan150drugsthat
includetablets,capsules,oralliquidsand
dry powders.Thecompanymanufactures
manykindsof drugintermediatesincluding
Acetylthiophene,TheobromineandP-
BromoToluene.Thecompanyismainly
involved in the productionandmarketingof
pharmaceuticalssuchasdrug
intermediates,formulations,andactive
pharmaceuticalingredients(API).
6. JubilantLife Sciences Limited
JubilantLife SciencesLimitedisanIndianpharmaceutical andlifesciencescompany.
ThecompanywasincorporatedasVam Organic ChemicalsLtd.in 1978.It has a
presenceinover 100 countrieswithgroundpresenceinIndia,North America, Europe
andChina. It hasan employeebaseof around6200. JubilantLifeSciences
manufacturesandsuppliesAPIs, SolidDosageFormulations,Radiopharmaceuticals,
Allergy TherapyProductsandLife ScienceIngredients,andprovidesservices in
ContractManufacturingofSterileInjectablesandDrugDiscoveryand Development.

5. Cadila Healthcare
CadilaHealthcareisanIndianpharma
company.Its headquartersarelocatedat
Ahmedabad,Gujarat,India. Cadila
Laboratorieswasfoundedby Ramanbhai
Patel andShri IndravadanModiin 1952.
Thecompanyhasemployeestrengthof
over 11000acrosstheworld. In 1995
CadilaHealthcarecameunderthePatel
familyandCadilaPharmaceuticalsLtd.
cameundertheModifamily, followingthe
split of the two families.Thecompany
develops andmanufactures
pharmaceuticalaswellasdiagnostic
products,skin careproducts,herbal
products,andother OTCproducts.The
various therapeutic segmentscoveredby
CadilaHealthcareareAnti-Infective, Anti-
Allergic,Anti-Epileptic,Anti-Osteoporosis,
Anti-Depressant, Gastrointestinals,
Sedative, Women’sHealthcare,Anti-
Rheumatic,Tranquilizers,Anti-Diabetic,
Anti-Psychotic, PainManagementand
Tadalafil.TheblockbusterdrugsareOflin
OD, Clodus,Zoldac,NeoLoridin,Ven-OD,
Isbis, Bonmax,Mexate,Cartup, Zyqin,
Oxeptal,Zytonin, Cefinar, Zycolchin,
Vageston, Xet, Espra, Aldren, Serlin,
Epsolin,Euglim,Olandus,Divalpro,
Topiram,Cytolog,Stilnite, Mifegest,
Dactive, Linid,Mosadac,Salazar,
Lamidus,andZydalis.
4. Aurobindo Pharma Ltd.
AurobindoPharmaLimitedisan Indian
pharmaandmanufacturingcompany.Its
headquartersarelocatedinHyderabad,India
with a marketbaseof over 125 countries.It
manufacturesgenericpharmaceuticalsand
active pharmaceutical ingredients(APIs)
mainlyfor six majortherapeutic/product
areas: antibiotics,gastroenterologicals,anti-
retrovirals, cardiovascularproducts,anti-
allergicsandcentralnervoussystem
products.Thecompanyalso hasa presence
in the manufactureofanti-diabeticsand
cephalosporins.AurobindoPharmastarted
with a singleunitmanufacturingSemi-
Synthetic Penicillin(SSP)atPondicherry,in
in 1988-89andis the marketleaderinSemi-
Synthetic Penicillintoday.Someof the
productsareRaloxifene,Atazanavir,
Aliskiren, Fumerate,Montelukastand
AmoxycillinTrihydrate.
3. Lupin Limited
LupinLimitedisan Indianpharma
companybasedinMumbai.The
company’sR&Dheadquartersarelocated
at the LupinResearchPark, nearPune
with morethan1200scientists. It has
employeebaseof 11355.It is alsothe
fastest growinggeneric pharmaceutical
companyinJapanandthe US, the two
largestpharmaceuticalmarketsofthe
world.It is alsothe 5th largest andthe
fastest growinggeneric pharmaceutical
player in South Africa. Lupinwas inDr.
D.B. Guptafoundedin1968. Lupinis one
of the largest manufacturersofTBdrugs.
Thecompanyhasa presenceinthe
Cardiovascular,Anti-Infectives, Asthma,
Diabetology,Pediatrics,GI, CNS and
NSAIDs therapy segments.It is alsoa
leaderin the Cephalosporinsegment.
Lupin’sbusinessareasare brandedand
generic formulations,advanceddrug
delivery systems to biotechnologyand
APIs. Lupinhas a presenceinmorethan
70 countriesinmarketslikeUSA,
Australia, SouthAfrica, Japan,Europe,
Indiaand the Philippines.
2. Cipla Limited
CiplaLimitedisan Indianpharma
Mumbai,India.It was foundedin 1935by
Dr. K. A. Hamied.It was originallyname
as 'TheChemical,Industrial&
PharmaceuticalLaboratories'andlater
condensedasCiplain1984from the
initialsof eachwordin the name.The
companyhasan employeebaseof
27,562worldwide.It has 34
manufacturingunitsinIndiaanda global
presencespanning170countries.The
companyoffers over 2000productsin
around65 therapeutic categories,inmore
than 40dosageforms. Ciplaalsohas a
hospicecalledthe'CiplaPalliativeCare
1. Dr.Reddy’s Lab
Dr. Reddy's LaboratoriesLtd.is anIndian
pharmacompany.Its headquartersare
locatedinAndhra Pradesh, India.Dr. Reddy’s
Labswas foundedby Anji Reddy. The
companyproducesandsellspharmaceuticals
in the form of over 190 medicationsand60
APIs in India andoverseas. It has employee
strength of 16,300worldwide.Someof the
majorAPIs of Dr.Reddy’sare Ibuprofen,
Naproxen,Sparfloxacinetc.Someofthe
majorbrandsof drugsof the companyare
Mintop,Atocor, Stamloand Reclimet.
 SalesRevenue: Rs. 8434cr.

andTrainingCentre'locatedinPune,for
terminallyillcancerpatients.Throughthis
hospice,Ciplaclaimstohave provided
medicinesandmedical servicesto8,500
patientstill date totally free of cost. Cipla
has a presenceintreatmentareasthat
includecardiovasculardisease,
respiratory, weightcontrol,diabetes,
urology, musculoskeletal,
neuropsychiatry, oncology,HIV-AIDS,
allergy, anti-infectives,analgesic,anti
malarial,dermatologyand
cosmeceuticals,gastroenterology,iron
chelators,nutritionalandophthalmic
products,hormonesandsteroids,and
women’shealthetc..Ciplais the first
pharmacompanyto manufacturethe
world’sfirst oralironchelator – by the
nameof Deferiprone.Ciplaalsohasa
presenceinthe veterinary andpet-care
segment.Themainproductsinthe
company’sportfolioareLamivudine,
Escitalopram (anti-depressant)and
Fluticasonepropionate.
SalesRevenue: Rs. 8202.42cr.

TalentOne TEAM
OurAnalysts are careeristsinsearch business;we builta team of expertswho createeveryday value to clientsinmeetingtheirtalent
strategy.
Industry Expert Advisors: We Keepinterviewingindustryexperts to gatherkey informationandlatesttrends in different industry,
technologyandbusinessoperations.We also consultwitha high-valuepanelof experts onsomeof ourprized mandates.We are a
verticallyintegratedtalent searchandselectioncompany
NEERAJ KUMAR
Founder& CEO
Neerajis an executivesearchenthusiast.An IIT Delhigraduate
with richglobalexperiencewithfirmslikeBritishTelecomand
BEA Systems, deliveringon-site technologysolutions,Neeraj
choseexecutivesearchashis next passionventure.
He leadsbusinessandis responsibleforbuildingTalentOne,a
worldclasssearchandselectionfirm.
Email –neeraj@talentone.in
LinkedIn – in.linkedin.com/in/neekum
MRINAL KRANT
SearchPracticePartner-Pharma|Medical Device|DrugSafety-
Technology-IndiaandUS
Morethan 8 years into PharmaConsulting,Technology,Drug
Safety and Devicehiring.Mrinalisa talent connoisseur,
passionateaboutresolving mystery of talent selection.Heplays
this alchemistroleashisdream to createan enviablesearch
practiceinever enigmatic worldofhiring.MrinalhasanMBAfrom
SymbiosisInstitute of BusinessManagementandclosetoa
decadeoflearningandexperimentingwithfactsandmyths of
humanresourcesapplications.SchneiderElectric’sAPC andZS
Associates area few companiesheworkedfor.
Email –mrinal@talentone.in
LinkedIn – in.linkedin.com/pub/mrinal-krant/6b/9b/938

Talent one indian pharma updates june 2015

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Viewers also liked

Viewers also liked (6)

Similar to Talent one indian pharma updates june 2015

Similar to Talent one indian pharma updates june 2015 (20)

Recently uploaded

Recently uploaded (20)

Talent one indian pharma updates june 2015